Alkermes plc, a Dublin-based biotech with executive offices in Waltham, has asked US regulators to approve its experimental treatment for schizophrenia.
The company Monday said it submitted a new drug application to the Food and Drug Administration for the drug candidate aripiprazole lauroxil, an antipsychotic that is injected into patients once a month.
That long-acting drug demonstrated “significant improvements” in patients’ schizophrenia symptoms in a late-state clinical treatment, compared to a placebo, according to the company.
Alkermes, which also has a research and development center in Waltham, markets more than 20 drugs and has a clinical pipeline of compounds to treat central nervous system disorders such as addiction, schizophrenia and depression.
Advertisement
Robert Weisman can be reached at robert.weisman@globe.com. Follow him on Twitter @GlobeRobW.